RxDoctor Payments Data

Mara Neville

Psychiatric/Mental Health · Marlton, NJNPI 1144929563

Payments from drug & device makers

$2,292in general payments, 2019–2025

Across 140 payments — averaging $16.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$474
  • Otsuka America Pharmaceutical, Inc.$348
  • Alkermes, Inc.$262
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$208
  • Vanda Pharmaceuticals Inc.$147
  • Tris Pharma Inc$145
  • plus $709 from 10 others

What the payments were for

  • Food & beverage$2,26799%
  • Education$261%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,292 in reported general payments places this provider in the 80th percentile of 1,212 psychiatric/mental health providers in New Jersey.

See all psychiatric/mental health providers in New Jersey

Medicare billing

Part B allowed, 2024
$20,506
Medicare patients
149
Services billed
337

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole14$27,666
VraylarCariprazine Hcl13$15,761
Lurasidone Hcl18$3,180
Desvenlafaxine Succinate ErDesvenlafaxine Succinate22$1,913
Lamotrigine122$1,659
Mirtazapine29$1,243
Aripiprazole49$1,142
Venlafaxine Hcl ErVenlafaxine Hcl38$898
Divalproex Sodium ErDivalproex Sodium16$888
Duloxetine Hcl34$809
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine31$778
Quetiapine Fumarate46$723
Ziprasidone Hcl16$636
Bupropion XlBupropion Hcl19$563
Risperidone23$525

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$348$27,66614 claims
AbbVieVraylar$99$15,76113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,212 psychiatric/mental health providers in New Jersey.

Other psychiatric/mental health in Marlton

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →